Pazopanib: A promising new agent in the treatment of soft tissue sarcomas

Future Oncology

Volumn 7, Issue 12, 2011, Pages 1373-1383

  Kasper, Bernd ^b   Hohenberger, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

angiogenesis inhibitor; pazopanib; renal cell carcinoma; soft tissue sarcoma; tyrosine kinase inhibitor

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TRABECTEDIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOSARCOMA; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD TOXICITY; CHONDROSARCOMA; DEPIGMENTATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEIOMYOSARCOMA; LIVER TOXICITY; LUNG CANCER; MELANOMA; NAUSEA; NEUROENDOCRINE TUMOR; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SOFT TISSUE SARCOMA; TREATMENT FAILURE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNITED STATES;

ANTINEOPLASTIC AGENTS; HUMANS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SARCOMA; SULFONAMIDES;

EID: 82455162605     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.116     Document Type: Article

References (37)

1. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a Phase II study from the European Organisation for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J. Clin. Oncol. 27(19), 3126-3132 (2009).
2. Kasper B, Thierry G, D'Hondt V, Gebhart M, Awada A. Novel treatment strategies for soft tissue sarcoma. Crit. Rev. Oncol. Hematol. 62(1), 9-15 (2007).
3. Schmitt T, Kasper B. New medical treatment options and strategies to assess clinical outcome in soft tissue sarcoma. Expert. Rev. Anticancer Ther. 9(8), 1159-1167 (2009).
4. Hayes AJ, Mostyn-Jones A, Koban MU et al. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br. J. Surg. 91(2), 242-247 (2004).
5. Wang J, Coltrera MD, Gown AM. Cell proliferation in human soft tissue tumors correlates with platelet-derived growth factor-B chain expression: an immunohistochemical and in situ hybridization assay. Cancer Res. 54(2), 560-564 (1994).
6. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. 23(3), 576-584 (2005).
7. Garcia-Carbonero R, Supko JG, Maki RG et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter Phase II and pharmacokinetic study. J. Clin. Oncol. 23(24), 5484-5492 (2005).
8. Maki RG, Wathen JK, Patel SR et al. Randomized Phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J. Clin. Oncol. 25(19), 2755-2763 (2007).
9. Schlemmer M, Reichardt P, Verweij J et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer 44(16), 2433-2436 (2008).
10. Schöffski I, Ray-Coquard L, Cioffi A et al. Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052). Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
11. Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY, Hohenberger P. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann. Oncol. 22(6), 1266-1272 (2011).
12. Chawla P, Blay J, Ray-Coquard IL et al. Results of the Phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). Presented at: 2011 ASCO Annual Meeting. Chicago, IL, USA, 3-7 June 2011.
13. Harris PA, Boloor A, Cheung M et al. Discovery of 5-[[4-[(2,3-dimethyl- 2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 51(15), 4632-4640 (2008).
14. Bukowski RM. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert. Rev. Anticancer Ther. 10(5), 635-645 (2010).
15. Kumar R, Knick VB, Rudolph SK et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 6(7), 2012-2021 (2007).
16. Keisner SV, Shah SR. Pazopanib - the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 71(4), 443-454 (2011).
17. Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13(1), 1-14 (2010).
18. GlaxoSmithKline. Investigator's Brochure for Pazopanib (GW786034) for oncology and ophthalmic indications. RR2002/00017/10. 28 February 2011.
19. Hurwitz HI, Dowlati A, Saini S et al. Phase I trial of pazopanib (GW786034), an oral multikinase angiogenesis inhibitor, in patients with advanced cancer: results of safety, pharmacokinetics, and clinical activity. Clin. Cancer Res. 15(12), 4220-4227 (2009).
20. Votrient™ (pazopanib) tablets, prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA (2010).
21. ® (sorafenib) tablets, prescribing information. Bayer HealthCare Pharmaceuticals Inc., Wayne, NJ, USA (2009).
22. ® (sunitinib) capsules, prescribing information. Pfizer Labs, New York, NY, USA (2010).
23. Shibata SLJ, Chung VM, Lenz H et al. A Phase I and pharmacokinetic single agent study of pazopanib (P) in patients (Pts) with advanced malignancies and varying degrees of liver dysfunction (LD). Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
24. Rini B, Al-Marrawi MY. Pazopanib for the treatment of renal cancer. Expert Opin. Pharmacother. 12(7), 1171-1189 (2011).
25. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
26. Van Glabbeke M, Verweij J, Judson J, Nielsen OS. Progression-free rate as the principal end point for Phase II trials in soft tissue sarcomas. Eur. J. Cancer 38(4), 543-549 (2002).
27. Van der Graaf WT, Blay J, Chawla SP et al. PALETTE: a randomized, double-blind, Phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy - an EORTC STBSG Global Network Study (EORTC 62072). Presented at: 2011 ASCO Annual Meeting. Chicago, IL, USA, 3-7 June 2011.
28. Routhouska S, Gilliam AC, Mirmirani P. Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor. Arch. Dermatol. 142(11), 1477-1479 (2006).
29. Sideras K, Menefee ME, Burton JK et al. Effect of pazopanib on hair and skin hypopigmentation: a series of three patients. Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
30. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061-1068 (2010).
31. Xu CF, Reck BH, Xue Z et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br. J. Cancer 102(9), 1371-1377 (2010).
32. Xu C, Reck BH, Goodman VL et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J. Hepatol. 54(6), 1237-1243 (2011).
33. Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28(13), 2137-2143 (2010).
34. Sleijfer A, Van Glabbeke M, Lamers C et al. Soluble factors (SF) associated with efficacy and toxicity of pazopanib (PZB) in advanced soft tissue sarcoma (STS) patients (pts): an EORTC-STBSG study. Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
35. Le Cesne A, Van Glabbeke M, Verweij J et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG Phase III trial. J. Clin. Oncol. 27(24), 3969-3974 (2009).
36. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. J. Clin. Oncol. 28(7), 1247-1253 (2010).
37. Hamberg P, Verweij J, Sleijfer S. (Pre-)Clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist 15(6), 539-547 (2010).